Disparities in Biomarker Testing for Metastatic Colorectal Cancer
By Arun Nagarajan, MD - Last Updated: March 19, 2025Arun Nagarajan, MD, of Cleveland Clinic Florida, discusses new research published in JAMA on biomarker testing disparities in metastatic colorectal cancer.
Advertisement
He explains how disparities in testing can affect overall survival and treatment outcomes for patients with mCRC, and how patient and provider education can play a role in improving the rates of testing.
Advertisement
Related Posts
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
Experts speak on the new face of CRC, the potential mechanisms for these trends, and how CRC screening programs should react.
Dr. Tie discusses the beneficial results seen with a ctDNA-guided approach, and touches on its role in future trials.
Dr. James Cleary discusses the use of HER2-directed therapies for the treatment of CRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.